Abstract: A storage module connects to a frame forming a door opening of a vehicle. The storage module includes a housing conforming to the door opening and extending into the compartment in an installed configuration. The storage module further includes an exterior panel disposed on a first side of the housing. The exterior panel conforms to an exterior surface of the vehicle enclosing the door opening. At least one storage compartment is disposed inside the housing and the compartment in the installed configuration. The storage compartment includes an access panel forming a portion of the exterior surface and forms a first storage volume.

Abstract: A method for controlling a vehicle includes determining, via a processor disposed in communication with a sensory device disposed in an interior surface of a cargo bin of a delivery vehicle, that a first package is loaded in the cargo bin, causing to scan, via the processor, a bar code disposed on an exterior surface of the first package, causing to measure, via a RADAR sensory device disposed in the cargo bin, dimensional information associated with the first package, determining, based on the dimensional information, that the cargo bin is loaded at full capacity, causing to illuminate an output device indicative that the cargo bin is loaded at full capacity, determining, via the processor, a cargo bin door closed status and generating, via the processor, an output indicating whether the vehicle is ready for delivery.

Abstract: A smart container for transporting items in transportation vehicles, e.g., an autonomous vehicle (AV), having heating/cooling capabilities, security features, unloading/loading assistance, and/or GPS cellular tracking for positional awareness, and methods of use thereof, are provided. The smart container includes an inductive charging module for receiving power from the vehicle. The container may provide information to facilitate delivery. When the vehicle arrives at a delivery destination, the customer may be provided a map of containers within the vehicle, and a specific container may provide an indication that it is the correct container. The customer may then provide a code to access the container. If a container is improperly removed, an alarm may be triggered and a notification may be provided to a third party.

Abstract: Tissue access devices and methods of using the same are disclosed. The devices can have a sensor configured to occlude a flow path by deflecting a membrane into the flow path when the devices become dislodged from tissue. The sensor can be configured to partially or fully occlude the flow path. The sensor can have a spring. The spring can be biased to move the sensor from a sensor first configuration to a sensor second configuration when a force applied by the sensor first surface against a non-sensor surface changes from a first force to a second force less than the first force. The membrane can be deflected into the flow path when the sensor is in the sensor second configuration.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.

Abstract: An adjustable pillow (1), which includes a casing (2) and a closable opening (12) to access the interior of the casing (2) where a plurality of small pillows (17) are contained. The small pillows (17) have filling (26) that provides support to the pillow (1) that is adjustable. The adjustment process involves a single variable of adjusting the quantity of small pillows (17) contained within the pillow (1) interior. This process allows incremental and simultaneous adjustments to the firmness, density, height and size of the pillow (1). Small pillows (17) are unique in shape, filling density and materials that allows them to self-adjust within the pillow (1) interior, creating a unified group of level filling (26) for the pillow. Small pillows (17) provide pleasing increments of adjustment that accommodates a wide range of sleeping positions and comfort preferences.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

Abstract: In one aspect, an apparatus includes a housing, a haptic element on at least a portion of the housing that has a non-discrete configuration and at least a first discrete configuration, a processor, a touch-enabled display operatively coupled to the processor, and a memory accessible to the processor. The memory bears instructions executable by the processor to initiate a function at the apparatus, and at least in part in response to initiation of the function, actuate a portion of the haptic element.

Abstract: One embodiment provides an apparatus, including: an arm; a head that attaches to the arm; the head comprising a camera; and a base attached to the arm; the base including: a power and data connector; a device operatively coupled to the power and data connector; wherein the camera shares the power and data connector with the device of the base. Other aspects are described and claimed.

Abstract: In one aspect, a case includes at least one exterior surface, at least one compartment internal to the exterior surface and in which at least one system component cars be placed, a strap removably engageable with the exterior surface, and a cable coupled to the strap that is useable to transmit at least one of data and power between two devices.

Abstract: One embodiment provides a display stand, including: a base supporting a dock; the dock having: a front that accommodates a display panel; a front face that extends upward from the front; and a back face that is substantially opposite to the front face; the back face including a cover that repositions to reveal an internal cavity disposed within the dock; the dock further including a surface forming a wall of the internal cavity, the surface having one or more power and data connectors. Other aspects are described and claimed.

Abstract: A device can include a processor; memory operatively coupled to the processor; a display housing that includes a display operatively coupled to the processor; a keyboard housing that includes a keyboard operatively coupled to the processor, a retractable camera operatively coupled to the processor, and a socket mechanism that translates the retractable camera between a retracted state and an extended state; and a hinge that couples the display housing to the keyboard housing.

Abstract: A device can include a processor; memory operatively coupled to the processor; a display housing that includes a display operatively coupled to the processor; a keyboard housing that includes a keyboard operatively coupled to the processor, a retractable camera operatively coupled to the processor, and a socket mechanism that translates the retractable camera between a retracted state and an extended state; and a hinge that couples the display housing to the keyboard housing.

Abstract: In one aspect, a first device includes a housing, at least one system component housed by the housing, a connector coupled to the housing that engages with a second device for exchange, between the first device and the second device, of at least one of data and power, and a first magnet coupled to the housing. The first magnet is coupled to the housing so that a first pole of the first magnet faces away from the first device to repel a first pole of a second magnet coupled to the second device when the first device is juxtaposed next to the second device in a first orientation relative to the second device.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.